**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

 

----

 

**FORM 20-F/A**

**(Amendment No. 2)**

**(Mark One)**

 

| **o**      | **REGISTRATION STATEMENT PURSUANT   TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934**                                     |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| ** ** | ** **                                                                                                                                              |
| **OR**     |
| ** ** | ** **                                                                                                                                              |
| **x**      | **ANNUAL REPORT PURSUANT TO SECTION 13   OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the fiscal year ended December   31, 2011** |
| ** ** | ** **                                                                                                                                              |
| **OR**     |
| ** ** | ** **                                                                                                                                              |
| **o**      | **TRANSITION REPORT PURSUANT TO   SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**                                                |
| ** ** | ** **                                                                                                                                              |
| **OR**     |
| ** ** | ** **                                                                                                                                              |
| **o**      | **SHELL COMPANY REPORT PURSUANT   TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**                                             |

 

Date of event requiring this shell company report . . . . . . . . . . . . . . . . . . .

 

**For the transition period from                       to                        **

 

Commission file number 001-32749

 

----

 
| **FRESENIUS MEDICAL CARE AG & Co. KGaA**           |
|--------------------------------------------------------|
| (Exact name of Registrant as specified in its charter) |
|                                                   |
| **FRESENIUS MEDICAL CARE AG & Co. KGaA**           |
| (Translation of Registrant’s name into English)   |
|                                                   |
| **Germany**                                            |
| (Jurisdiction of incorporation or organization)        |

 

----

 
| **Else-Kröner Strasse 1, 61352 Bad Homburg,   Germany**                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------|
| (Address of principal executive offices)                                                                                      |
|                                                                                                                          |
| **Josef Dinger, +49 6172 608 2522,   Josef.Dinger@FMC-AG.com,**

**Else-Kröner Strasse 1, 61352 Bad Homburg,   Germany** |
| (Name, Telephone, E-mail and/or Facsimile number and Address of   Company Contact Person)                                     |

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

| Title of each   class                                     |   | Name of each   exchange on which registered |
|-----------------------------------------------------------|--------|---------------------------------------------|
| American Depositary Shares representing Preference Shares |   | New York Stock Exchange                     |
| Preference Shares, no par value                           |   | New York Stock Exchange(1)                  |
| American Depositary Shares representing Ordinary Shares   |   | New York Stock Exchange                     |
| Ordinary Shares, no par value                             |   | New York Stock Exchange(1)                  |

 

----

(1)  Not for trading, but only in connection with the registration of American Depositary Shares representing such shares.

 

Securities registered or to be registered pursuant to Section 12(g) of the Act:

 
| **None**         |
|------------------|
| (Title of Class) |

 

----

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

 
| **6 7/8 % Senior Notes due 2017** |
|-----------------------------------|
| (Title of Class)                  |

 

----

** **

**EXPLANATORY NOTE**

 

This Amendment No. 2 on Form 20-F/A (“Amendment”) amends the Annual Report on Form 20-F filed with the Securities and Exchange Commission by Fresenius Medical Care AG & Co. KGaA (the “Registrant”) on February 23, 2012 (“Original Filing Date”), as amended by Amendment No. 1 on Form 20-F/A filed February 24, 2012 (together, the “Original Report”), pursuant to which the Registrant furnished a copy of Exhibit 4.30 (the “Exhibit”). The Registrant is filing this Amendment solely to re-file the Exhibit to provide certain previously omitted portions for which the Registrant has determined that confidential treatment is not required. Other than the re-filing of the Exhibit, no part of the Original Report is being amended, and the filing of this Amendment should not be understood to mean that any other statements contained therein are true or complete as of any date subsequent to the Original Filing Date.

 

**EXHIBITS**

 
| **Exhibit No.** | ** ** | ** **                                                                                                                                                             |
|----------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                 |       |                                                                                                                                                                   |
| 4.30                 |       | Second Amendment dated September 30,   2011 to the License, Distribution, Manufacturing and Supply Agreement (filed   herewith). (1)                              |
|                 |       |                                                                                                                                                                   |
| 12.1                 |       | Certification of Chief Executive Officer of   the general partner of the Registrant Pursuant to Section 302 of the   Sarbanes-Oxley act of 2002 (filed herewith). |
|                 |       |                                                                                                                                                                   |
| 12.2                 |       | Certification of Chief Financial Officer of   the general partner of the Registrant Pursuant to Section 302 of the   Sarbanes-Oxley act of 2002 (filed herewith). |

 

----

(1) Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission.

 

2

----

 

**SIGNATURES**

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

DATE: August 2, 2012

 
|   | FRESENIUS MEDICAL CARE AG & Co.   KGaA             |
|--------|-------------------------------------------------------------|
|   | a partnership limited by shares, represented   by:          |
|   |                                                        |   |
|   | FRESENIUS MEDICAL CARE MANAGEMENT AG, its general   partner |
|   |                                                        |   |
|   | By:                                                         | /s/ DR. BEN J. LIPPS |
|   | Name:                                                       |  Dr. Ben J. Lipps |
|   | Title:                                                      |  Chief Executive Officer and  Chairman of the Management Board of the |
|   |                                                        |  General Partner |
|   |                                                        |   |
|   |                                                        |   |
|   |                                                        |   |
|   | By:                                                         | /s/ MICHAEL BROSNAN |
|   | Name:                                                       |  Michael Brosnan |
|   | Title:                                                      |  Chief Financial Officer and  Member of the Management Board of the |
|   |                                                        |  General Partner |
|        |                                                             |  |  |

 

3

----